NuGenerex Immuno-Oncology, Inc., an oncology company, focuses on the modulation of the immune system to treat cancer. The company is developing immunotherapeutic products and vaccines. It is developing AE37, a peptide immunotherapeutic vaccine, which is in Phase II clinical trials for the treatment of metastatic triple negative breast cancer. The company was formerly known as Antigen Express, Inc. The company was founded in 1993 and is based in Miramar, Florida. NuGenerex Immuno-Oncology, Inc.is a subsidiary of Generex Biotechnology Corporation.

Biotecnología

Dr. Jason B. Terrell M.D.

Chief Medical Officer

Mr. Richard D. Purcell

Executive Vice President of R&D and Director

Mr. Anthony S. Crisci CPA, Esq.

Corporation Counsel, Chief Legal Officer, Sec. & Director

Mr. Mark  Corrao

Chief Financial Officer

Mr. Joseph  Moscato

Chief Executive Officer, Pres & Chairman

Dr. Eric  von Hofe Ph.D.

Chief Scientific Officer

Nombre	Capitalización
hVIVO plc	0M
VistaGen Therapeutics, Inc.	0M
BioVaxys Technology Corp.	0M
MedMira Inc.	0M
Regenicin, Inc.	0M
Vascular Biogenics Ltd.	0M
CorMedix Inc.	0M
Wave Life Sciences Ltd.	0M
Immuron Limited	0M
Aptevo Therapeutics Inc.	0M

NuGenerex Immuno-Oncology, Inc.

NuGenerex Immuno-Oncology, Inc. Lista de competidores

Principales competidores